Why TransMedics Fell 15.7% This Week

Source The Motley Fool

Shares of organ transplant innovator TransMedics Group (NASDAQ: TMDX) fell 15.7% through Thursday trading, according to data from S&P Global Market Intelligence.

TransMedics was the target of an activist short-seller late last week, and on Monday of this week, the company responded to the accusations at an industry health conference.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »

While the stock initially bounced back a bit after the conference, it continued to fall through the week, as investors still appear to be skittish over the controversy.

Scorpion attacks

Last Friday, Scorpion Capital published a 342-page short report -- yes, 342 pages! -- detailing an alleged six-month investigation into TransMedics and its business practices.

TransMedics has developed a new type of organ transplant technology called the Organ Care System (OCS), which provides oxygen and nutrients to organs during transport. This new technology aims to supplant the current standard of cold storage, which is basically freezing the organ.

Scorpion's report includes a number of allegations. Some of these are that the OCS doesn't work nearly as well as the company lets on, that TransMedics uses thuggish tactics to get hospitals to take on its organs and to push sales, and that the company has antagonized customers by withholding organs if payments haven't come through. Scorpion also pointed to emerging competitive concerns, among other issues.

On Monday, TransMedics gave a full-throated defense of its business in a press release, and also in its presentation at the J. P. Morgan Healthcare Conference. The press release said Scorpion's report had "no merits" and that it "fails to accurately represent TransMedics' business, technology, diverse culture and steadfast focus on delivering exceptional products and services to meet the needs of the global transplant community." The company also said it was engaging a law firm to discuss legal options.

In the first part of his presentation at the conference, CEO Waleed Hassanein suggested that since TransMedics is in the process of disrupting established players in organ transplant, those competitors may be "driving a lot of the dynamics you guys are seeing" regarding the short report.

Who should investors believe?

TransMedics can't seem to catch a break recently, as the company disappointed investors with a growth slowdown in its third-quarter earnings release and fourth-quarter guidance. Its CFO also stepped down back in December. The stock is now down 66% from its all-time highs, reached just this past summer.

If the Scorpion report turns out to have some truth, there is obviously further downside. However, if TransMedics is correct and its technology and business are eventually vindicated, the upside potential is still substantial, according to the company's long-term guidance.

Interested investors may want to take a page out of Peter Lynch's book and "invest in what you know." For instance, if you happen to know a surgeon, other physician, nurse, or administrator who works with organ transplants, questioning them as to whether they've worked with TransMedics' OCS and how they did with the technology could yield insights into this controversial stock. Otherwise, it may be hard to build conviction until more information comes to light.

Should you invest $1,000 in TransMedics Group right now?

Before you buy stock in TransMedics Group, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and TransMedics Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $818,587!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

See the 10 stocks »

*Stock Advisor returns as of January 13, 2025

JPMorgan Chase is an advertising partner of Motley Fool Money. Billy Duberstein and/or his clients have no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase and TransMedics Group. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Bitcoin Price Bounces Back—Can It Finally Break Resistance?Bitcoin price started a recovery wave above the $83,500 zone. BTC is now consolidating and might struggle to settle above the $85,500 zone. Bitcoin started a decent recovery wave above the $83,500
Author  NewsBTC
Apr 02, Wed
Bitcoin price started a recovery wave above the $83,500 zone. BTC is now consolidating and might struggle to settle above the $85,500 zone. Bitcoin started a decent recovery wave above the $83,500
placeholder
U.S. March Nonfarm Payroll Preview: Even If Data Aligns with Expectations, Financial Markets May Not Escape the Fate of VolatilityOn 4 April 2025, the United States will release its March Nonfarm Payrolls (NFP) data. The market consensus currently anticipates job growth of 128,000, a decline from February’s 151,000 (Figure 1). W
Author  TradingKey
Apr 02, Wed
On 4 April 2025, the United States will release its March Nonfarm Payrolls (NFP) data. The market consensus currently anticipates job growth of 128,000, a decline from February’s 151,000 (Figure 1). W
placeholder
Japanese Yen spikes to multi-week high against USD after Trump’s tariffs announcementThe Japanese Yen (JPY) jumped to a three-week top against its American counterpart during the Asian session on Thursday after US President Donald Trump imposed sweeping trade tariffs.
Author  FXStreet
Yesterday 02: 36
The Japanese Yen (JPY) jumped to a three-week top against its American counterpart during the Asian session on Thursday after US President Donald Trump imposed sweeping trade tariffs.
placeholder
Bitcoin price reacts as Gold sets fresh record highs after Trump’s reciprocal tariffs announcementBitcoin price plunges towards $82,000 as Gold soars past $3,150 after US President Donald Trump imposed new tariffs on Israel and UK, triggering global markets turbulence.
Author  FXStreet
Yesterday 02: 38
Bitcoin price plunges towards $82,000 as Gold soars past $3,150 after US President Donald Trump imposed new tariffs on Israel and UK, triggering global markets turbulence.
placeholder
Bitcoin Price Forecast: Tariff volatility sweeps over $200 billion from crypto marketsBitcoin (BTC) price hovers around $83,000 at the time of writing on Thursday after it failed to close above a critical resistance level the previous day.
Author  FXStreet
16 hours ago
Bitcoin (BTC) price hovers around $83,000 at the time of writing on Thursday after it failed to close above a critical resistance level the previous day.
goTop
quote